TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

P3 Health Partners Inc (PIII)

Healthcare Medical Care Facilities
9.80 $
-3.8% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at P3 Health Partners Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Trading Day

Previous Close
10.20$
Open
9.80$
Day High
10.80$
Day Low
9.80$
Volume
12,644shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
1.50 $ 16.50 $
02/02/2026 05/28/2026

Current price 9.80 $ — 55% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
0.1$B
Shares Outstanding
3Mio.
Float
41.7%
Beta
1.6

Performance

Perf. 1M
-27.50%
Perf. 3M
45.00%
Perf. 6M
18.10%
YTD Performance (%)
243.60%
52-Week-High Distance
-36.8%
Perf. 1Y
32.48%
Perf. 3Y
-91.14%
Perf. 5Y
-98.01%
Perf. Since Inception
-97.97%

Technical Indicators

MA 38 Days
10.90$
MA 50 Days
11.40$
MA 200 Days
6.00$
RSI (14)
45.3
Volatility 30 Days
80.8%
Volatility 250 Days
157.8%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
0.0
PEG
P/B
0.6
P/S
0.05
EV/EBITDA
-1.9
Price/FCF

Profitability

Gross Margin
-0.8%
EBIT Margin
Net Margin
-8.6%
Return on Equity
-6,952.6%
Return on Assets
-19.2%

Balance Sheet & Safety

Equity Ratio
negative equity
Debt/Equity
-0.4
warning zone
Altman Z″
-5.74
Piotroski
6 out of 9

Growth

Sales Growth Last Quarter
3.50%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
-2.76%
Forward Sales Growth
8.03%
Forward EPS Growth

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
Top 10%
RS Rating
97
EPS Rating
42
Piotroski
6 out of 9
Fundamental Rating
D (42 out of 100)
warning zone
Altman Z″
-5.74

AI Rating

Uses AI

P3 Health Partners (Value-Based-Care-Anbieter) verkauft keine KI, bestätigt aber in beiden 10-Ks ausdrücklich den operativen Einsatz von KI, Machine Learning und automatisierten Entscheidungstechnologien im eigenen Geschäft sowie den KI-Ausbau der eigenen Versorgungsplattform.

View the full file — quotes, sources, reviewed filings
„We use artificial intelligence (“AI”), machine learning, and automated decision-making technologies (collectively, “AI Technologies”) in our business."

Wir setzen Künstliche Intelligenz („KI“), maschinelles Lernen und automatisierte Entscheidungstechnologien (zusammen „KI-Technologien“) in unserem Geschäft ein.

10-K · 2026-03-26 · View SEC filing
„In addition, we use artificial intelligence (“AI”), machine learning, and automated decision-making technologies (collectively, “AI Technologies”) in our business."

Darüber hinaus setzen wir Künstliche Intelligenz („KI“), maschinelles Lernen und automatisierte Entscheidungstechnologien (zusammen „KI-Technologien“) in unserem Geschäft ein.

10-K · 2025-03-28 · View SEC filing
„maintain and improve the infrastructure underlying our platform, including our data protection, implementation of artificial intelligence for appropriate functions to the extent permitted by applicable law, intellectual property and cybersecurity"

die Infrastruktur unserer Plattform aufrechterhalten und verbessern, einschließlich unseres Datenschutzes, der Einführung Künstlicher Intelligenz für geeignete Funktionen im gesetzlich zulässigen Rahmen, des geistigen Eigentums und der Cybersicherheit

10-K · 2026-03-26 · View SEC filing

Filings Reviewed: 10-Q 2026-05-14 · 10-Q 2025-11-14 · 10-Q 2025-08-14 · 10-Q 2025-05-15 · 10-K 2026-03-26 · 10-K 2025-03-28

Rated on July 8, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 9.80 $
Price Target (average) 14.00 $

The price target sits 42.9% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

10. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
-1.89 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 370.7 $M Q4 2025: Q1 · 373.2 $M Q1 2025: Q2 · 355.8 $M Q2 2025: Q3 · 345.3 $M Q3 2025: Q4 · 384.8 $M Q4 2026: Q1 · 386.4 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -17.62 371 6.90 -15.80 -57 -57
2025: Q1 -6.16 373 -3.90 -5.50 -34 -34
2025: Q2 -6.12 356 -6.20 -5.70 -17 -17
2025: Q3 -9.50 345 -4.70 -9.10 -15 -16
2025: Q4 -22.71 385 3.80 -19.60 -26 -26
2026: Q1 0.37 386 3.50 0.30 -28 -28
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

P3 Health Partners Inc., ein patientenzentriertes und ärztlich geführtes Unternehmen für Populationsgesundheitsmanagement, bietet hochwertige Versorgungsdienstleistungen in den USA an.

Employees320
HeadquartersHenderson, NV
Websitep3hp.org
IPO Date6. Apr 2021

Management

Management
Name Title Birth Year
Aric Coffman M.D. CEO, President & Director 1974
Amir Bacchus M.B.A., M.D. Co-Founder, Chief Medical Officer & Director 1965
Leif Pedersen Chief Financial Officer 1976
William Bettermann Executive VP & COO
Devery Goodey Senior Vice President of Technology
Sarah Bussmann B.S.N., CRNI, M.H.A., R.N. Chief Administrative Officer
Todd M. Smith Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Kassi Belz APR Executive Vice President of Marketing & Communications
Shelly Martin Regional President of Nevada & Arizona
Erin Mastagni Market President of Oregon

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?